SCHEMBL3013690

SCHEMBL3013690

CC(C)c1cc(C(C)C)c(S(=O)(=O)C2CCN(c3nc(Cc4ccc(Cl)cc4)cs3)CC2)c(C(C)C)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FABP4 P15090 2/20 0.37
MAPT P10636 5/20 0.36
SMN1; SMN2 Q16637 3/20 0.35
LMNA P02545 3/20 0.35
MAPK1 P28482 2/20 0.35
HRH3 Q9Y5N1 1/20 0.34
OGA O60502 2/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
CACNA1G O43497 1/20 0.33
CACNA1H O95180 1/20 0.33
CACNA1I Q9P0X4 1/20 0.33
ALDH1A1 P00352 1/20 0.32
PSEN1 P49768 1/20 0.32
PSEN2 P49810 1/20 0.32
APH1B Q8WW43 1/20 0.32
NCSTN Q92542 1/20 0.32
APH1A Q96BI3 1/20 0.32
PSENEN Q9NZ42 1/20 0.32
TSHR P16473 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3019281 0.93 HRH3 (0.35) FABP4MAPTSMN1; SMN2LMNAMAPK1
SCHEMBL3006880 0.92 OGA (0.36) FABP4MAPTSMN1; SMN2LMNAMAPK1
SCHEMBL3016738 0.92 SMN1; SMN2 (0.36) MAPTSMN1; SMN2HRH3OGAKMT2A
SCHEMBL3004517 0.91 LMNA (0.37) FABP4MAPTSMN1; SMN2LMNAHRH3
SCHEMBL3012900 0.91 DNM1L (0.37) LMNAMAPK1HRH3OGAMEN1
SCHEMBL3009892 0.91 CACNA1G (0.37) FABP4MAPTSMN1; SMN2LMNAHRH3
SCHEMBL3016316 0.90 FABP4 (0.37) FABP4MAPTSMN1; SMN2LMNAMAPK1
SCHEMBL3021693 0.90 OGA (0.34) LMNAMAPK1HRH3OGAMEN1
SCHEMBL3014593 0.89 CACNA1G (0.42) FABP4MAPTSMN1; SMN2LMNAHRH3
SCHEMBL3000434 0.89 RAB9A (0.38) MAPTSMN1; SMN2HRH3OGAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA FABP4 3254/4885MAPT 18/4885SMN1; SMN2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.